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Abstract  1 
The concept of replacement therapy in haemophilia is changing significantly thanks to the 2 
switch from standard products to extended half-life products. These novel drugs are showing 3 
beneficial effects overcoming current prophylaxis limitations by reducing the infusion frequency, 4 
maintaining a higher trough level to ensure a lower risk of bleeding, and making treatment 5 
significantly less distressing to patients by improving the quality of life. Real-life data on the 6 
efficacy of novel drugs and their impact on routine management of haemophilia A and B patients is 7 
still limited. This manuscript reports the results of a European survey conducted by the European 8 
Association for Haemophilia and Allied Disorders (EAHAD) at the beginning of 2018 on the 9 
clinical management of patients using extended half-life recombinant FVIII and FIX fusion 10 
products, since at the time of the survey none of the PEGylated products were available yet. We 11 
report data on the efficacy of these novel drugs by 33 European haemophilia centers that have 12 
already switched to extended half-life fusion products, showing a significant reduction in the 13 
number of infusions and a satisfactory trough levels in the clinical care of haemophilia patients, 14 
with a greater impact for haemophilia B.   15 
 16 
  17 
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INTRODUCTION 1 
 2 
The clinical picture of haemophilia is characterized by bleeding episodes that occur either 3 
spontaneously, in the most severe cases, or as a result of trauma. Repeated spontaneous bleeding 4 
episodes mainly affect muscles and joints and lead to chronic arthropathy, with loss of joint 5 
movement and fixed flexion deformity (1,2). Prophylaxis with standard FVIII and FIX products is 6 
effective at preventing joint damage and decreasing the frequency of hemorrhagic events, as 7 
demonstrated in young boys with severe haemophilia (3), but does not assure a complete protection 8 
from bleeding with a maximum trough level of 1-2%. However, prophylaxis protocols with these 9 
products require recurrent venipuncture (2-3 times per week), and this is one of the main reasons 10 
why patients, particularly children and adolescents, decline or discontinue treatment.  11 
Extending the half-life of recombinant products is thought to ease patient management by 12 
reducing dosage frequency and prolonging protection from bleeding, which could improve 13 
compliance and make this therapy less distressing to the patient (4). Over the last ten years, 14 
recombinant factor (F)VIII products for haemophilia A and FIX products for haemophilia B have 15 
been remodeled to prolong their half-lives by chemical modification using polyethylene glycol 16 
(PEG) polymers and fusion to the fragment crystallizable (Fc) region of an IgG1 or, alternatively, to 17 
human albumin (5-7). The half-lives of the new EHL recombinant FVIII products are 18 
approximately 1.5- to 1.6-fold longer compared with standard products (8-10) reducing the 19 
frequency of infusions by  30%-35% with a prophylaxis regimen of twice weekly using 20 
recombinant FVIII fused to Fc or once every five or seven days using PEGylated concentrates (8-21 
10). These prophylaxis schemes maintain a higher trough FVIII level than standard products: a3 22 
IU/dL (3%) (11).  23 
EHL recombinant FIX products with a 3-6 fold half-life extension of compared with standard 24 
products have certainly simplified the prophylactic regimen of haemophilia B patients, who receive 25 
infusions once every 7-14 days in the prophylactic regimen while maintaining FIX trough levels 26 
above 5-10% (8-10). Moreover, an ongoing clinical trial with recombinant FIX albumin fusion is 27 
investigating whether the dosing interval could be extended to 21 days (clinicaltrials.gov: 28 
NCT02053792) (12). Clinical trial outcomes have shown for both EHL recombinant FVIII and FIX 29 
drugs that prophylaxis regimens are associated with very low annualized bleeding rates (ABRs) 30 
compared to on-demand treatment (11,13-16). These results make such therapies significantly less 31 
distressing to the patient (particularly in the case of FIX) and  are likely to improve their quality of 32 
life (17,18).  33 
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EHL products have been licensed at different times in the USA and Europe. In the USA, EHL 1 
products were available much earlier than in Europe due to the differences between US Food and 2 
Drug Administration (FDA) and European Medicines Agency (EMA) regulations for authorizing 3 
new products (19). At the beginning of 2018, EHL products available in Europe were limited to 4 
recombinant FVIII and FIX fusion products. Real-life evidences have greater value than clinical 5 
trials as they provide more accurate responses to questions about patient health and the safety and 6 
effectiveness of medical products. Data on the real-life effectiveness of EHL products is still limited 7 
and has been reported mainly at international meetings and in a few published reports (20-29).  8 
In this paper, we report the preliminary data on real-life experiences at European haemophilia 9 
treatment centers (HTCs), according to a survey administered by the European Association for 10 
Haemophilia and Allied Disorders (EAHAD) on the adoption and clinical management of patients 11 
using available novel EHL FVIII and FIX products. 12 
The survey was conducted at the beginning of 2018, when a limited number of new EHL 13 
products were available in European countries. 14 
 15 
MATERIALS AND METHODS 16 
We administered a survey to determine the efficacy of EHL products after they became 17 
available in several European countries. At the time of the survey (January 2018), a limited number 18 
of EHL products were available: recombinant FVIII and FIX fused to Fc (rFVIII-Fc and rFIX-Fc) 19 
and recombinant FIX fused to albumin (rFIX-FP). As for PEGylated products, PEGylated FVIII 20 
(BAY94-9027) was not yet approved by the regulatory agency in Europe (EMA), and PEGylated 21 
FVIII (BAX855) was approved the same month as our survey (January 2018) but was not yet 22 
available at European HTCs. A decision on glycoPEGylated products (N8-GP) was still pending, 23 
and recombinant FIX glycoPEGylated (N9-GP) had been licensed in 2017 but was not yet marketed 24 
during the survey.  25 
Our unbiased approach to data collection provides a snapshot of the real European experience, 26 
and could be used as a baseline from which to compare results over time.  27 
 The questionnaire was sent by the EAHAD, in January 2018, to 48 certified European HTCs 28 
belonging to the European Haemophilia Network (EUHANET) 29 
(https://www.euhass.org/aspxpages/certcentres.aspx). 30 
Each HTCs was asked how long time their center had been using each of the EHL products, 31 
what type of EHL product was available at their center, the percentage of haemophilia A and B 32 
patients who had switched to EHL products, and the beneficial effects of EHL products in terms of 33 
number of infusions, achieved trough level, and percent reduction in bleeding events.  34 
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Ethical approval was not required for this study, as the data was collected anonymously and not 1 
individually. Our questionnaire did not request specific data for individual patients but general 2 
information about the efficacy observed by the HTCs after switching their patients to EHL 3 
products.  4 
 5 
RESULTS 6 
Thirty-three European HTCs out of 48 submitted a completed questionnaire to EAHAD.  7 
The recombinant FVIII fusion product (rFVIII-Fc) was the EHL drug used routinely for 8 
haemophilia A at 76% of the responding centers (25/33). In detail, 55% (18/33) had been regularly 9 
using the rFVIII-Fc product for more than a year, 18% (6/33) had experience with this product for 10 
three to seven months and only 3% (1/33) had been using it for less than three months. The 11 
remaining 24% (8/33) had not yet used it in clinical care (Figure 1). Of these, six European HTCs 12 
(Portugal, Czech Republic, Serbia, Bosnia Herzegovina and two centers in Turkey) reported that the 13 
new rFVIII-Fc was not available yet, while at the remaining two HTCs, one in Bulgaria and one in 14 
France, the product was available but not being used by the physicians.  15 
As for EHL recombinant FIX concentrates, 64% of the responding haemophilia centers (21/33) 16 
were regularly using these new drugs. Fourteen centers had experience with both rFIX-Fc and rFIX-17 
FP products, while four used only the rFIX-Fc product and three used only the rFIX-FP. Forty 18 
percent (13/33) of the centers had been using the EHL drugs regularly for more than a year, 21% 19 
(7/33) for three to seven months, and 3% (1/33) for less than three months. Thirty-six percent 20 
(12/33) had not yet used EHL recombinant FIX fusion products for the clinical management of 21 
haemophilia B (Figure 1). Of these, at five European HTCs (Portugal, Serbia, Bosnia Herzegovina, 22 
and two centers in Turkey), the new EHL recombinant FIX products were not commercially 23 
available, while at HTCs in Greece, Finland, Spain (Madrid), UK (London), and France (Paris), the 24 
products were available but the centers had not yet switched their patients to the EHL products. 25 
 26 
Efficacy data on EHL drug for haemophilia A (rFVIII-Fc)    27 
Twenty-five out of 33 HTCs submitted a reply on the efficacy of the EHL recombinant FVIII fusion 28 
product and about 72% of these centers (18/25) had switched less than 10% of their haemophilia A 29 
patients from standard products to rFVIII-Fc drug. Two of them (8%) had switched 60-80% of their 30 
patients, and none had switched more than 80% (Figure 2).   31 
The positive effects of EHL rFVIII-Fc were evaluated considering the reduction in infusions, 32 
trough FVIII level and decrease in bleeding events.  33 
6 
 
Sixty-six percent of the responding HTCs (15/23) reported a 30% or greater reduction in the 1 
number of infusions (Figure 3). The number of infusions decreased by 10% for 17% of the HTCs 2 
(4/23), while another 17% reported a decrease of 20%.  3 
Regarding trough level, 33% of the HTCs (7/21) achieved a trough FVIII level of 1-3% and 4 
67% (14/21) achieved a trough FVIII level of 3-5%, while none observed a trough level of more 5 
than 5% (Figure 3). 6 
In terms of bleeding events, most centers (57%; 12/21) observed a decrease of less than 20%, 7 
28% (6/21) reported a reduction of the bleeds of 20-50%, while only 5% (1/21) observed a decrease 8 
of 50-99%. Ten percent of the responding HTCs (2/21) reported a 100% decrease in bleeds (Figure 9 
3).       10 
 11 
Efficacy data on EHL drugs for haemophilia B (rFIX-Fc and rFIX-FP) 12 
Forty-three percent of responding HTCs (9/21) using EHL drugs for haemophilia B had switched 13 
10-40% of their haemophilia B patients from standard therapy to the EHL recombinant FIX 14 
concentrates. Nineteen percent (4/21) had switched the majority of their patients (80-100%) to EHL 15 
products (Figure 2).         16 
All responding HTCs revealed a reduction in infusions of more than 30% (Figure 3).  17 
The clinical use of EHL recombinant FIX products led to an FIX trough level of at least 5-10% 18 
in 67% of centers (14/21), while 19% (4/21) achieved an FIX trough level of 3-5% (Figure 3). Only 19 
three centers (14%) observed a low trough level of 1-3%.     20 
A 100% decrease in bleeding events was reported in almost one third of the responding centers 21 
(5/18), while 33% (6/18) observed a decrease of 20-50% and 39% of the centers (7/18) revealed a 22 
decrease in bleeding episodes of less than 20% (Figure 3).    23 
   24 
DISCUSSION 25 
The concept of haemophilia replacement therapy is changing thanks to the introduction and 26 
licensing of novel EHL recombinant FVIII and FIX products in the European market. A well 27 
designed study to assess the real efficacy and safety of these novel EHL drugs is needed to allow 28 
proper use in the routine clinical care of bleeding events, prophylaxis, and surgical management of 29 
patients with haemophilia A and B, and to work toward the possible revision of prophylactic 30 
treatment schedules.  31 
In this report, we provide very preliminary data on the efficacy of a few novel EHL drugs 32 
(rFVIII-Fc, rFIX-Fc and rFIX-FP) that were commercially available in Europe at the time of the 33 
EAHAD survey, with 33 responding European HTCs. The survey suffers from a few limitations. 34 
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First, our data does not include PEGylated FVIII and FIX products, which were not yet available in 1 
Europe at the time of the survey so results are limited to the three EHL fusion products mentioned 2 
above. Additionally, we do not report any data on safety assessment, which is not completely 3 
known and requires a proper long-term surveillance using a consensus minimal dataset collection 4 
tool as recommended by the ISTH Scientific and Standardization Subcommittee (SSC) working 5 
group (30). The onset of inhibitors is an important safety issue relating to newly licensed EHL 6 
drugs, to be addressed when data from the ongoing previously untreated patients (PUPs) studies is 7 
available. Another significant safety issue is the potential risk of PEG accumulation in haemophilia 8 
associated with long-term and chronic administration (31,32). Long-term surveillance is required to 9 
understand the effect of longstanding PEG exposure. The currently available information obtained 10 
from the approved PEGylated products does not indicate any specific human toxicity, as these 11 
products are not for life-long use as is the case for haemophilia.   12 
The outcomes reported by the 33 responding HTCs to the EAHAD survey showed a beneficial 13 
effect of EHL FVIII products in reducing the number of infusions, by  in 66% of the 14 
responding HTCs using the new drugs; in  trough levels, where a value of 3-5% was reached by 15 
67% of centers; and in decreasing bleeding episodes by  at 86% (18/21) of responding HTCs. 16 
The number of patients switched to EHL drugs was still low, with the majority of HCTs (72%) 17 
having switched less than 10% of their haemophilia A patients. Recent real-world experiences have 18 
also confirmed our survey data that treatment with the new EHL recombinant FVIII products 19 
reduces the number of infusions by 30-40% with a substantially lower ABR in patients receiving 20 
prophylaxis compared to on-demand treatment (20-29,33,34).   21 
Our survey on EHL recombinant FIX showed a significant reduction in infusion frequency at 22 
100% of the centers, with 67% achieving a trough FIX level of at least 5 to10%. Forty-three percent 23 
of HTCs have switched 10-40% of their patients from standard therapy to EHL drugs. Recent 24 
publications on real-world outcomes have shown a 50-60% reduction in infusions, confirming our 25 
preliminary analysis at European HTCs (21,22,28,29,33-37). Therefore, this very preliminary data 26 
obtained by survey reflects beneficial efficacy effects in both haemophilia A and haemophilia B 27 
using EHL fusion products, with especially pronounced results in haemophilia B. These novel 28 
products have almost made it possible to improve severe haemophilia A patients to moderate 29 
phenotype by following an infusion schedule of two times a week or every five days, and to alter 30 
the clinical picture of haemophilia B patients from severe to mild phenotype through one single 31 
infusion every 7 or 10 days. It would be worthwhile to conduct another survey of the same 32 
European HTCs in the near future, to monitor the usage rate, efficacy, and also the safety of these 33 
novel products.  34 
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These new drugs are also becoming more widely used in clinical practice in the United States, 1 
such that the proportion of patients switched to prophylaxis with EHL recombinant FVIII and FIX 2 
has increased substantially since FDA approval. Recent data by Aledort et al (33) showed that the 3 
number of haemophilia A patients switched to EHL recombinant FVIII increased from 13% in 2014 4 
to 21% in 2018, and for the haemophilia B patients, the number rose from 25% in 2014 to 57% in 5 
2018 (33). Recent data presented during the ASH 2018 annual meeting by the American 6 
Thrombosis and Hemostasis Network (ATHN) reported that 21% of patients with moderate or 7 
severe haemophilia A and 42% of patients with moderate or severe haemophilia B have received 8 
prophylaxis using an EHL product (34). The shift to EHL drugs is transforming haemophilia care 9 
by achieving improved bleeding control and higher trough levels, thereby improving long-term joint 10 
protection.  11 
More real-life experience is necessary to provide insights into how physicians and patients 12 
make treatment choices and into the dosing regimens used in the clinical setting. Evaluating the 13 
safety of these new drugs is of the utmost importance and should be monitored through careful, 14 
long-term observation of any unexpected effects occurring after marketing authorization. Recently, 15 
following recommendations published by the ISTH Scientific and Standardization Subcommittee 16 
(SSC) on Factor VIII, Factor IX and Rare Coagulation Disorders for post-registration surveillance 17 
of new drugs in haemophilia (30), a new pharmacovigilance system for EHL products has been 18 
developed in the form of a mobile phone app (mAPPHemo) that patients and their physicians can 19 
use to record treatments and any complications that may arise. This tool, or any other national or 20 
international surveillance system such as the pharmacovigilance program of EUHASS, will be 21 
helpful in identifying all known and unknown side effects of these newly licensed products. 22 
Recently, the EMA also reported the importance of long-term surveillance. 23 
In conclusion, the arrival of novel EHL drugs and their widespread adoption have changed the 24 
clinical management of haemophilia A by reducing the number of infusions and achieving higher 25 
trough levels and better protection. These effects appear to be even more significant for 26 
haemophilia B patients. The safety and efficacy of new concentrates has to be monitored 27 
continuously in order to update haemophilia management and develop evidence-based guidelines 28 
for the correct use of new EHL drugs in the routine clinical care of haemophilia.   29 
  30 
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FIGURE LEGENDS 1 
Figure 1. Number and percentage of European HTCs by usage time of new EHL products for the 2 
treatment of haemophilia A (left) and B (right). 3 
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